Biocon Biologics, Viatris receive EC approval for biosimilar insulin as part Kixelle

Biocon Biologics Ltd., a subsidiary of Bengaluru-headquartered Biocon Ltd., has announced that Kixelle, a biosimilar insulin as part co-developed with NASDAQ-listed Viatris Inc., has received marketing authorisation approval from the European Commission. This follows the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, a Biocon statement said on Friday.
Read more...

;